Category News

HS-10365

China’s NMPA Accepts New Drug Application for HS-10365 Capsules to Treat RET Fusion-Positive NSCLC

CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that the New Drug Application(NDA) of the Group’s innovative drug “HS-10365 capsules”, a potent…

Read MoreChina’s NMPA Accepts New Drug Application for HS-10365 Capsules to Treat RET Fusion-Positive NSCLC

WuXi Biologics Receives 2025 Global Customer Value Leadership Award from Frost & Sullivan

Recognition highlights WuXi Biologics’ commitment to delivering exceptional value and innovative solutions to its global clients. WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been honored with the Frost &…

Read MoreWuXi Biologics Receives 2025 Global Customer Value Leadership Award from Frost & Sullivan

IDWeek 2025: Shionogi Highlights Data Supporting Cefiderocol’s sRole in Tough-to-Treat Infections

New findings underscore Cefiderocol’s efficacy and reliability in managing complex, multidrug-resistant bacterial infections. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presents new data at IDWeek 2025, demonstrating broad activity of Fetroja®/Fetcroja®…

Read MoreIDWeek 2025: Shionogi Highlights Data Supporting Cefiderocol’s sRole in Tough-to-Treat Infections

Roche’s Gazyva Secures FDA Approval for Lupus, Marking Expansion Beyond Cancer

The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting…

Read MoreRoche’s Gazyva Secures FDA Approval for Lupus, Marking Expansion Beyond Cancer
Hansoh Pharma HS-20089

Hansoh Pharma Presents Phase 2 Data on HS-20089 for Platinum-Resistant Ovarian Cancer at ESMO 2025

The investigational B7-H4–targeted antibody–drug conjugate HS-20089 demonstrates encouraging efficacy and manageable safety in patients with platinum-resistant ovarian cancer. Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase 2 study findings of HS-20089, a B7-H4-targeted Antibody-drug Conjugate, in patients…

Read MoreHansoh Pharma Presents Phase 2 Data on HS-20089 for Platinum-Resistant Ovarian Cancer at ESMO 2025